Provided for client's internal research purposes only. May not be further copied, distributed, sold or published in any form without the prior consent of the copyright owner.
Malaysia capable of producing quality vaccines
It will elevate the country to become a hub for vaccine production and increase confidence in the use of vaccines, says PM
by S BIRRUNTHA
MALAYSIA is able to pave the way for the production of its own quality, effective and safe vaccine products in accordance with the conditions set by the National P h a r m a c e u t i c a l R e g u l a t o r y Agency, said Prime Minister (PM) Datuk Seri Ismail Sabri Yaakob.
Ismail Sabri said that it is through the implementation of the National Vaccine Development Roadmap (PPVN) and the establishment of the Malaysian Genome and Vac- cine Institute (MGVI) which is a government initiative to strengthen the country's vaccine development ecosystem.
The PM added this will elevate the country to become a hub for vaccine production and increase confidence in the use of vaccines.
"Through the implementation of PPVN and the establishment of
According to Ismail Sabri, more job opportunities will also be created for Malaysian families who can improve the living standards and the health of the people
MGVI, highly skilled h u m a n capi- tal in various fields of research, especially those related to health and vaccines will be born.
"More job o p p o r t u n i t i e s will also be c r e a t e d for M a l a y s i a n
f a m i l i e s w h o c a n i m p r o v e t h e living standards and the health of the people," he said in a statement yesterday.
Ismail Sabri noted that the local vaccine development is not just
AUTHOR: S BIRRUNTHA SECTION: CORPORATE MALAYSIA PAGE: 6 PRINTED SIZE: 418.00cm² REGION: KL MARKET: Malaysia PHOTO: Full Color ASR: MYR 4,404.00 ITEM ID: MY0045840890
Page 1 of 3 02 NOV, 2021
Malaysia capable of producing quality vaccines
The Malaysian Reserve, Malaysia
Provided for client's internal research purposes only. May not be further copied, distributed, sold or published in any form without the prior consent of the copyright owner.
limited to just Covid-19 vaccine production but will also focus on the development of cholera, as well as head and neck cancer vaccine.
As a vaccine-producing country, he said Malaysia will have auto- n o m y over the p r o c u r e m e n t of materials and methods of vaccine production.
Meanwhile, Science, Technology and Innovation Minister Datuk Seri Dr Adham Baba said PPVN sets the production of vaccines in two phases, namely in short term (one to five years) and long term (five to 10 years).
He added that the development of this vaccine aims to produce h u m a n vaccines for domestic use especially in the National Covid-19 I m m u n i s a t i o n P r o g r a m m e to ensure the country is ready to face any pandemic threat in the future.
According to Dr A d h a m , the PPVN framework is divided into six priority areas, namely govern- ance, vaccine manufacturing infra- structure, clinical studies, h u m a n capital development, vaccine tech- nology and development procure- ment, and vaccine communication.
He said PPVN emphasises col- laboration between government,
scientists, medical practitioners and industry players through eco- systems, governance and strategic approaches to provide an ecosys- tem of collaboration between the v a r i o u s p a r t i e s involved f r o m a m o n g ministries, agencies and manufacturing companies at the n a t i o n a l l e v e l , r e g i o n a l a n d international.
"The governance of MGVI will be led and centralised under the Institute of Biotechnology National, an agency under the Science, Tech- nology and Innovation Ministry.
"Meanwhile, research activities will be implemented in decentral- ised facilities together with four centres of excellence, namely Vac- cine Discovery Centre of Excel- lence, Pre-clinical Research Centre of Excellence, Clinical Research Centre of Excellence and Process Development Centre of Excellence to leverage capabilities, expertise and existing facilities," he noted.
Dr Adham said MGVI is believed to be able to increase collaboration and provide access to research facilities to meet the needs of vac- cine development, in line with the National Science, Technology and Innovation Policy 2021-2030.
AUTHOR: S BIRRUNTHA SECTION: CORPORATE MALAYSIA PAGE: 6 PRINTED SIZE: 418.00cm² REGION: KL MARKET: Malaysia PHOTO: Full Color ASR: MYR 4,404.00 ITEM ID: MY0045840890
Page 2 of 3 02 NOV, 2021
Malaysia capable of producing quality vaccines
The Malaysian Reserve, Malaysia
Provided for client's internal research purposes only. May not be further copied, distributed, sold or published in any form without the prior consent of the copyright owner.
SUMMARIES
Malaysia capable of producing quality vaccines by S BIRRUNTHA It will elevate the country to become a hub for vaccine production and increase confidence in the use of vaccines, says PM MALAYSIA is able to pave the way for the production of its own quality, effective and safe vaccine products in accordance with the conditions set by the National P h a r m a c e u t i c a l Regulatory Agency, said Prime Minister (PM) Datuk Seri Ismail Sabri Yaakob. Ismail Sabri said that it is through the imple...
AUTHOR: S BIRRUNTHA SECTION: CORPORATE MALAYSIA PAGE: 6 PRINTED SIZE: 418.00cm² REGION: KL MARKET: Malaysia PHOTO: Full Color ASR: MYR 4,404.00 ITEM ID: MY0045840890
Page 3 of 3 02 NOV, 2021
Malaysia capable of producing quality vaccines
The Malaysian Reserve, Malaysia
